Brief: Oncopeptides Q3 Operating Loss Narrows To SEK 338.9 Mln
24/11/2021 07:28
Nov 24 (Reuters) - Oncopeptides AB ONCO.ST :
* ONCOPEPTIDES PUBLISHES Q3 2021 REPORT
* Q3 NET SALES AMOUNTED TO SEK 54.3 M (0.0)
* Q3 OPERATING LOSS AMOUNTED TO SEK 338.9 M (LOSS: 383.5)
Source text for Eikon: ID:nWkrFHJy7
Further company coverage: ONCO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy